	US 11,911,383 B2
	Oral solution formulation
Ashwinkumar Jain, East Lyme, CT (US); and Weili Yu, Pawcatuck, CT (US)
Assigned to Pfizer Inc., New York, NY (US)
Appl. No. 17/055,102
Filed by Pfizer Inc., New York, NY (US)
PCT Filed May 3, 2019, PCT No. PCT/IB2019/053650 § 371(c)(1), (2) Date Nov. 12, 2020, PCT Pub. No. WO2019/220253, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/835,278, filed on Apr. 17, 2019.
Claims priority of provisional application 62/671,208, filed on May 14, 2018.
Prior Publication US 2021/0205309 A1, Jul. 8, 2021
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01)]

18 Claims

1. An oral aqueous solution comprising 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (palbociclib), or a lactate or malate salt thereof, and a buffer system comprising lactic acid or malic acid, wherein the palbociclib, or a lactate or malate salt thereof, is at a solution concentration of up to about 40.0 mq/mL.